To assess clinical relevance of overlapping hits—Trp53, Dap5, Serf2, and Sh2d3c—(Figure 2A) from all three screens, we queried a cohort of patients with melanoma receiving TIL therapy,124,125 where RNA-seq was performed for TIL products prior to infusion (Besser M.J., RNA-seq data unpublished). The gene discussed is SH2D3C; the disease is melanoma.